Prognostic Significance of MTOR Pathway Component Expression in Neuroendocrine Tumors | Zendy

Zhi Rong Qian | Zendy; Monica TerMinassian | Zendy; Jennifer A. Chan | Zendy; Yu Imamura | Zendy; Susanne M. Hooshmand | Zendy; Aya Kuchiba | Zendy; Teppei Morikawa | Zendy; Lauren K. Brais | Zendy; Anastassia Daskalova | Zendy; Rachel Heafield | Zendy; Xihong Lin | Zendy; David C. Christiani | Zendy; Charles S. Fuchs | Zendy; Shuji Ogino | Zendy; Matthew H. Kulke | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Prognostic Significance of MTOR Pathway Component Expression in Neuroendocrine Tumors

Author(s) -

Zhi Rong Qian,

Monica TerMinassian,

Jennifer A. Chan,

Yu Imamura,

Susanne M. Hooshmand,

Aya Kuchiba,

Teppei Morikawa,

Lauren K. Brais,

Anastassia Daskalova,

Rachel Heafield,

Xihong Lin,

David C. Christiani,

Charles S. Fuchs,

Shuji Ogino,

Matthew H. Kulke

Publication year - 2013

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2012.46.6946

Subject(s) - pi3k/akt/mtor pathway , neuroendocrine tumors , pten , medicine , protein kinase b , rptor , cancer research , everolimus , immunohistochemistry , mechanistic target of rapamycin , tsc2 , p70 s6 kinase 1 , oncology , biology , signal transduction , microbiology and biotechnology

Clinical studies have implicated the mechanistic target of rapamycin (serine/threonine kinase; MTOR) pathway in the regulation of neuroendocrine tumor (NET) growth. We explored whether expression of MTOR pathway components has prognostic significance in NET patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research